ca channel
-
Upload
kency-doney -
Category
Documents
-
view
218 -
download
0
Transcript of ca channel
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 1/30
CALCIUM CHANNEL BLOCKERS
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 2/30
INOTROPIC AND CHRONOTROPIC
ACTIVITY
´ Calcium channel blockers decrease the force of
contraction of the myocardium (muscle of the
heart). This is known as the negative inotropiceffect of calcium channel blockers.
´ Calcium channel blockers also slow down the
conduction of electrical activity within the heart, by
blocking the calcium channel during the plateau
phase of the action potential of the heart This
results in a negative chronotropic effect
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 3/30
MECHANISM OF ACTION
´ Calcium channel blockers work by blocking voltage-gated calcium channels in cardiac muscle and blood
vessels. This decreases intracellular calcium leading
to a reduction in muscle contraction.
´ In blood vessels, a decrease in calcium results in less
contraction of the vascular smooth muscle and
therefore an increase in arterial diameter (CCBs do
not work on venous smooth muscle), a phenomenoncalled vasodilation
´ With a relatively low blood pressure, the afterload on
the heart decreases.
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 4/30
CLASSIFICATION
Dihydropyridine
´ They are often used to reduce systemicvascular resistance and arterial pressure,but are not used to treat angina because the
vasodilation and hypotension can lead toreflex tachycardia.
´ Dihydropiridine calcium channel blockerscan worsen proteinuria in patients with
nephropathy.
´ This CCB class is easily identified by thesuffix "-dipine".
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 5/30
NON-DIHYDROPYRIDINE
´ P henylalkylamine
´ They are relatively selective for myocardium,
reduce myocardial oxygen demand and
reverse coronary vasospasm, and are often
used to treat angina.
´ They have minimal vasodilatory effects
compared with dihydropyridines and
therefore cause less reflex tachycardia´ Eg: Verapamil, Gallopamil
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 6/30
BENZOTHIAZEPINE
´ They are an intermediate class betweenphenylalkylamine and dihydropyridines in their
selectivity for vascular calcium channels.
´ By having both cardiac depressant and
vasodilator actions, benzothiazepines are able to
reduce arterial pressure without producing the
same degree of reflex cardiac stimulation caused
by dihydropyridines.
Eg: Diltiazem
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 7/30
INDICATIONS
´ High blood pressure
´ Angina
´ Abnormal heart rhythms
´ Pulmonary hypertension
´ Raynaud's syndrome
´ Cardiomyopathy
´ Subarachnoid hemorrhage.
´ Prevention of migraine headaches.
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 8/30
AMLODIPINE
´ GENERIC NAME : Amlodipine
´ TRADE NAME : Norvasc
ACTION
´ Inhibits the transport of calcium into myocardial andvascular smooth muscle cells, resulting in inhibitionof excitation-contraction coupling and subsequentcontraction
´ Systemic vasodilation resulting in decreased bloodpressure
´ Coronary vasodilation resulting in decreasedfrequency and severity of attacks of angina
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 9/30
INDICATIONS
Alone or with other agents in the management of hypertension, angina pectoris, and vasospastic(Prinzmetal's) angina
´ PHARMACOKINETICS
Absorption: Well absorbed after oral administration(64-90%)Distribution: Probably crosses the placenta
Protein Binding: 95-98%Metabolism and Excretion: Mostly metabolized bythe liverHalf-life: 30-50 hr (increased in geriatric patients
and patients with hepatic impairment
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 10/30
CONTRAINDICATIONS
´ Hypersensitivity´ Blood pressure <90 mmHg
Use Cautiously in:
´ Severe hepatic impairment (dosage reductionrecommended)
´ Geriatric patients (dosage reductionrecommended; increased risk of hypotension)
´ Aortic stenosis
´ History of CHF
´ Pregnancy, lactation, or children (safety notestablished)
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 11/30
ADVERSE REACTIONS
CentralNervous System: headache, dizziness,
fatigue,
Cardio Vascular : peripheral edema, angina,
bradycardia, hypotension, palpitations,
Gastro Intestinal: gingival hyperplasia, nausea,
Dermatology: flushing
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 12/30
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 13/30
NURSE¶S RESPONSIBILTY
´ Monitor blood pressure and pulse before therapy, during dose titration, and periodically during therapy. Monitor ECGperiodically during prolonged therapy
´ Monitor intake and output ratios and daily weight. Assessfor signs of CHF (peripheral edema, rales/crackles,dyspnea, weight gain, jugular venous distention)
´ May be administered without regard to meal
´ Angina: Assess location, duration, intensity, andprecipitating factors of patient's anginal pain
´ Lab T est Considerations: Total serum calcium
concentrations are not affected by calcium channelblockers
´ Advise patient to take medication as directed, even if feeling well. Take missed doses as soon as possible unlessalmost time for next dose; do not double doses. May need
to be discontinued gradually
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 14/30
VERAPAMIL
´ GENERIC NAME : Verapamil
´ TRADE NAME : Calan, Calan SR, Isoptin
ACTION´ Inhibits the transport of calcium into myocardial
and vascular smooth muscle cells, resulting in
inhibition of excitation-contraction coupling and
subsequent contraction
´ Decreases SA and AV conduction and prolongs
AV node refractory period in conduction tissue
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 15/30
INDICATIONS
´ Management of hypertension, angina pectoris,and/or vasospastic (Prinzmetal's) angina
´ Management of supraventricular arrhythmias andrapid ventricular rates in atrial flutter or fibrillation
´ PHARMACOKINE
T IC S
Absorption: 90% absorbed after oral administration,but much is rapidly metabolized, resulting inbioavailability of 20-25%
Distribution: Small amounts enter breast milkProtein Binding: 90%Metabolism and Excretion: Mostly metabolized by theliver
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 16/30
CONTRAINDICATIONS/PRECAUTIONS
´ Hypersensitivity
´
Sick sinus syndrome´ 2nd- or 3rd-degree AV block (unless an
artificial pacemaker is in place)
´ BP <90 mmHg
´ CHF, severe ventricular dysfunction, orcardiogenic shock, unless associated withsupraventricular tachyarrhythmias
´ Concurrent IV beta blocker therapy
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 17/30
ADVERSE REACTIONS
Central Nervous System: abnormal dreams, anxiety,
confusion, dizziness/lightheadedness, drowsiness,headache, jitteriness, nervousness, psychiatricdisturbances, weakness,Eye, ENT: blurred vision, disturbed equilibrium,
epistaxis, tinnitus,Respiratory : cough, dyspnea, shortness of breath,Cardio Vascular : arrhythmias, CHF, bradycardia,chest pain, hypotension, palpitations, peripheral
edema, syncope, tachycardia,Gastro Intestinal : abnormal liver function studies,anorexia, constipation, diarrhea, dry mouth,dysgeusia, dyspepsia, nausea, vomiting,
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 18/30
CONT¶D«.
Genito Urinary : dysuria, nocturia, polyuria, sexualdysfunction, urinary frequency,
Dermatology: dermatitis, erythema multiforme,
flushing, increased sweating, photosensitivity,pruritus/urticaria, rash,
Endocrine: gynecomastia, hyperglycemia,
Hematology: anemia, leukopenia,
thrombocytopenia,
Metabolic: weight gain,
MusculoSkeletal : joint stiffness, muscle cramps,
Neurology: paresthesia, tremor
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 19/30
ROUTE AND DOSAGE
Oral : 80-120 mg 3 times daily, increased asneeded. Extended-release preparations--120-240mg/day as a single dose; may be increased as
needed (range 240-480 mg/day)´ Intra Venous (Adults ): 5-10 mg (75-150 mcg/kg);
may repeat with 10 mg (150 mcg/kg) after 15-30minAVAILABILITY
´ T ablets: 40 mg, 80 mg, 120 mg
´ Injection: 2.5 mg/m in 2- and 4-ml vials,
ampules, and syringes
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 20/30
NURSE¶S RESPONSIBILITY
´ Monitor blood pressure and pulse before therapy, during dosage titration, and periodically throughout therapy. MonitorECG periodically during prolonged therapy. Verapamil maycause prolonged PR interval
´ Monitor intake and output ratios and daily weight. Assess for
signs of CHF
´ Angina: Assess location, duration, intensity, and precipitating
factors of patient's anginal pain
´ Arrhythmias: Monitor ECG continuously during administration.Notify physician promptly if bradycardia or prolonged
hypotension occurs. Emergency equipment and medicationshould be available. Monitor blood pressure and pulse beforeand frequently during administration
´ Lab T est Considerations: Total serum calcium concentrationsare not affected by calcium channel blockers
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 21/30
CONT¶D«.
´ Monitor serum potassium periodically. Hypokalemia
increases the risk of arrhythmias and should becorrected
´ Monitor renal and hepatic functions periodicallyduring long-term therapy. May cause increase inhepatic enzymes after several days of therapy, whichreturn to normal on discontinuation of therapy
´ Do not confuse verapamil with Virilon (testosterone).Do not confuse Covera (verapamil) with Provera(medrosyprogesterone)
´ Oral: Administer verapamil with meals or milk tominimize gastric irritation
´ IntraVenous: Patients should remain recumbent for atleast 1 hr after IV administration to minimize
hypotensive effects
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 22/30
DILTIAZEM
´ GENERIC NAME : diltiazemTRADE NAME : Cardizem
´ MODE OF ACTION
´ Inhibits transport of calcium into myocardialand vascular smooth muscle cells, resulting ininhibition of excitation-contraction coupling andsubsequent contraction
´ Systemic vasodilation resulting in decreasedblood pressure
´ Coronary vasodilation resulting in decreasedfrequency and severity of attacks of angina
´
Suppression of arrhythmias
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 23/30
INDICATIONS
´ Hypertension
´ Angina pectoris and vasospastic (Prinzmetal's) angina
´ Supraventricular tachyarrhythmias and rapid ventricular rates in atrial flutter or
fibrillation
´ Management of Raynaud's syndrome
PHARMACOKINETICS
Absorption: Well absorbed, but rapidly metabolized after oral administration
Distribution: Unknown
Protein Binding: 70-80%
Metabolism and Excretion: Mostly metabolized by the liver (CYP 3A4 enzyme system)
Half-life: 3.5-9 hr
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 24/30
CONTRAINDICATIONS
´ Hypersensitivity
´ Sick sinus syndrome
´ 2nd- or 3rd-degree AV block (unless anartificial pacemaker is in place)
´ Blood pressure <90 mmHg
´
Recent MI or pulmonary congestion´ Concurrent use of rifampin
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 25/30
ADVERSE REACTIONS
Central Nervous System: abnormal dreams, anxiety, confusion, dizziness,
drowsiness, headache, nervousness, psychiatric disturbances,
weakness,
Eye ENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus,
Respiratory : cough, dyspnea,
CarddioVascular : ARRHYTHMIAS, CHF, peripheral edema, bradycardia,
chest pain, hypotension, palpitations, syncope, tachycardia,
Gastro Intestinal : abnormal liver function studies, anorexia, constipation,
diarrhea, dry mouth, dysgeusia, dyspepsia, nausea, vomiting,
Genito Urinary : dysuria, nocturia, polyuria, sexual dysfunction, urinary
frequency
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 26/30
CONT¶D«««
Dermatology : dermatitis, erythemamultiforme, flushing, increased sweating,
photosensitivity, pruritus/urticaria, rash,
Endocrine : gynecomastia, hyperglycemia,
Hematology: anemia, leukopenia,
thrombocytopenia,
Metabolic : weight gain,
MusculoSkeletal : joint stiffness, musclecramps,
Neuroolgy : paresthesia, tremor,
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 27/30
ROUTE AND DOSAGE
Oral : 30-120 mg 3-4 times daily or 60-120 mg twice dailyas SR capsules or 180-240 mg once daily as CD or XRcapsules or LA tablets (up to 360 mg/day)
´
IntraVenous : 0.25 mg/kg; may repeat in 15 min with adose of 0.35 mg/kg. May follow with continuousinfusion at 10 mg/hr (range 5-15 mg/hr) for up to 24 hr
AVAILABILITY
´ T ablets: 30 mg, 60 mg, 90 mg, 120 mg
´ Injection: 5 mg/ml in 10-ml vials, 25 mg ready-to-usesyringes (Lyo-Ject)
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 28/30
NURSE¶S RESPONSIBILITY
´ Monitor blood pressure and pulse before therapy,
during dose titration, and periodically during therapy.Monitor ECG periodically during prolonged therapy.May cause prolonged PR interval
´ Monitor intake and output ratios and dailyweight.Assess for signs of CHF (peripheral edema,rales/crackles, dyspnea, weight gain, jugular venousdistention)
´ Arrhythmias: Monitor ECG continuously during administration. Report bradycardia or prolonged
hypotension promptly. Emergency equipment andmedication should be available. Monitor bloodpressure and pulse before and frequently during administration
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 29/30
CONT¶D«.
´ Lab T est Considerations: Total serum calciumconcentrations are not affected by calcium channelblockers
´ Monitor serum potassium periodically. Hypokalemia
the risk of arrhythmias and should be corrected´ Monitor renal and hepatic functions periodically
during long-term therapy. May cause in hepaticenzymes after several days of therapy, which returnto normal on discontinuation of therapy
´ Do not confuse Cardizem (diltiazem) with Cardene(nicardipine). Do not confuse Cardizem LA withCardene SR
8/7/2019 ca channel
http://slidepdf.com/reader/full/ca-channel 30/30
THANK YOU